KRYS News and Press, Krystal Biotech Inc. From 06/22/22

PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking appr...

PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palo...

In a bear market, Krystal still shows that strong execution can be lucrative. They will file a BLA this quarter. The market potential is huge. For further details see: Krystal Biotech: High Potential, Buy-At-Dips Stock

PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), a...

Krystal Biotech press release (NASDAQ:KRYS): Q1 GAAP EPS of -$1.99 misses by $0.93. Cash, cash equivalents, and investments totaled $468M on March 31, 2022. “Our primary objective in 2022 is to prepare for the potential approval and launch of B-VEC in the U.S.” said Krish S...

Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022 FDA allows dosing at a patient’s home in the Open Label Extension Study of B-VEC for the treatment of DEB Positive Cli...

PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill...

April 28, 2022 Download PDF PITTSBURGH, April 28, 2022 (GLOBE NEWSWIRE) --  Jeune Aesthetics, Inc. (“Jeune Aesthetics”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced the formation and members...

PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extens...

The following slide deck was published by Krystal Biotech, Inc. in conjunction with this event. For further details see: Krystal Biotech (KRYS) AAD GEM-3 Phase 3 Data Presentation - Slideshow